Core Viewpoint - *ST亚太 is a company in the fine chemical sector, focusing on the research, production, and sales of pharmaceutical and pesticide intermediates, but it faces significant challenges in terms of revenue and profitability compared to industry peers [1][2]. Financial Performance - In Q3 2025, *ST亚太 reported revenue of 353 million, ranking 15th among 16 companies in the industry, significantly lower than the top competitor, Satellite Chemical, which had revenue of 34.77 billion, and the industry average of 4.28 billion [2]. - The net profit for the same period was -41.78 million, placing the company 13th in the industry, far behind the leading company, Satellite Chemical, which reported a net profit of 3.76 billion, and below the industry average of 200 million [2]. Financial Ratios - As of Q3 2025, *ST亚太's debt-to-asset ratio was 95.98%, a significant increase from 75.80% in the previous year, well above the industry average of 46.56% [3]. - The gross profit margin for Q3 2025 was 10.60%, slightly up from 8.66% year-on-year, but still below the industry average of 11.02% [3]. Management Compensation - The chairman, Chen Zhijian, received a salary of 720,000 in 2024, an increase of 420,000 from the previous year [4]. - The general manager, Ma Bing, maintained a salary of 720,000 in 2024, unchanged from 2023 [4]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 25.26% to 18,100, while the average number of circulating A-shares held per shareholder decreased by 20.16% to 17,800 [5].
*ST亚太的前世今生：2025年三季度营收3.53亿排行业15，净利润-4178万排13，资产负债率95.98%远高于行业平均
Xin Lang Zheng Quan·2025-10-31 12:02